Anonymous
Guest
Anonymous
Guest
LOL @ being "go to lab" - having zero revenue and no savior.
PS - Abbott will not be buying Neo, what is in it for them, clients with just above break even margins?
I dunno ... I've seen stranger things. Abbott could use their lab to for companion diagnostics and "low margin clients" would yeild a nice price for them - especially if they are diversifying their menu with higher margin tests.